Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration - PD-CP-Y1

Next Previous
Trial Profile

A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration - PD-CP-Y1

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary) ; Fluorescein
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Sponsors Rophibio

Most Recent Events

  • 11 Sep 2025 This trial has been early terminated in Poland, Slovakia, Croatia and Bulgaria (reason for all countries:Sponsor decision) according to Clinical Trials Information System
  • 11 Sep 2025 New trial record
  • 13 Mar 2025 According to Ropibio media release, the U.S. Biologics License Application (BLA) is expected to be submitted between 2026 and 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top